All In Biotech

Drug Trial Radar · NCT07788105

Efficacy and Safety of Lanoracopan in the Treatment of PNH

Efficacy and Safety of Lanoracopan Hydrochloride in the Treatment of Paroxysmal Nocturnal Hemoglobinuria: A Prospective, Single-Center Real-World Study

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Peking Union Medical College HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 26, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimed to evaluate the efficacy and safety of Lanoracopan Hydrochloride in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria, PNH

Interventions

  • Lanoracopan HydrochlorideDrug

    400mg bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. rate of adverse events (AEs)Time frame: During treatment, an average of 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.